focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.25
Bid: 8.20
Ask: 8.30
Change: -0.34 (-3.95%)
Spread: 0.10 (1.22%)
Open: 8.50
High: 8.50
Low: 8.26
Prev. Close: 8.60
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Net Asset Value calculation as at 31 March 2023

2 May 2023 11:38

RNS Number : 1282Y
Agronomics Limited
02 May 2023
 

2 May 2023

Agronomics Limited

("Agronomics" or the "Company")

Net Asset Value calculation as at 31 March 2023

Agronomics Limited (AIM:ANIC), the leading listed company focused on the field of cellular agriculture, announces that its unaudited Net Asset Valuation ("NAV") calculation as at closing on 31 March 2023 was 16.14 pence per share, broadly unchanged from 16.37 pence per share at 31 December 2022. Net Assets stand at £160 million, including investments of £131 million and uninvested cash of £29 million.

The share price of 10.90 pence at the 31 March 2023 close represents a discount of 32% to the NAV per share. The average discount to NAV per share over the last 12-month period was 4%. Under IFRS, the Company's unquoted investments are generally carried at cost or the most recent priced funding round.

Richard Reed, Chairman of Agronomics, commented: -

"Agronomics welcomed a new company to the portfolio this quarter, through its participation in the successful US$ 3.3 million Pre-seed financing of Wild Microbes, a company developing next-generation microbes for biomanufacturing.

This quarter also saw the second approval of a cultivated chicken product by the US Food and Drug Administration ("FDA"), with Good Meat receiving a 'No Questions letter'. The FDA is one of the most stringent regulatory bodies globally for food safety, and we still await the US Department of Agriculture to approve a cultivated meat product, allowing companies to begin commercialisation. We expect to see more regulatory approvals in the US for cultivated meat in the near term."

Corporate

On 23 February 2023, the Company announced the appointment of Marisa Drew to the Board of Directors. Marisa Drew is the inaugural Chief Sustainability Officer ("CSO") of Standard Chartered Bank Plc, responsible for setting the bank's sustainability strategy and the delivery of the firm's commitment to net zero carbon emissions by 2050 as well as overseeing the sustainable finance client-facing activities of the bank.

Financing

During the quarter ended 31 March 2023, the Company received notification of warrants being exercised. A total of 1,142 new ordinary shares were issued following the warrant exercise, for proceeds of £342.60. These funds, together with existing cash resources, will be utilised to provide finance for opportunities within the field of cellular agriculture, both by supporting existing companies, as well as identifying new opportunities in which to invest.

Investment review

On 25 January 2023, Liberation Labs Inc announced the acquisition of the land for its launch facility, which we believe will be the first dedicated, purpose-built, commercial, precision fermentation plant globally for food production.

On 7 February 2023, cultivated meat company CellX Limited announced the signing of a strategic partnership agreement with food manufacturing specialists Shanghai Tofflon Science and Technology Co., Ltd., aiming to accelerate the scale-up of cultivated meat in the Asian market with a new purpose-built facility.

On 23 February 2023, Agronomics participated in Wild Microbes US $3.3 million pre-Seed funding round, with a US$ 0.5 million investment. The investment was completed in the form of a Simple Agreement for Future Equity, and will provide Agronomics on conversion with an approximate equity ownership of 4.17% on a fully diluted basis. Wild Microbes' proprietary technology will allow it to genetically engineer novel microbial strains for use as host-organisms to produce proteins and other high value molecules.

 

 

Unaudited to

31 March 2023

£

Current Assets

 

 

 

Investments

130,895,484

 

Uninvested cash and deposits

 29,254,287

 

Trade and other receivables

 93,021

Current Liabilities

 

 

 

Trade and other creditors

(52,161)

Net Assets

 

160,190,631

Capital and Reserves

 

 

 

Share capital

992

 

Share premium

134,209,188

 

Retained earnings

25,980,451

Net assets

 

160,190,631

Shares in Issue

 

992,244,668

Net Asset Value per share

 

16.14 pence

The quoted investments within the portfolio are valued under IFRS at bid price.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014, as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

For further information please contact:

Agronomics

Limited

Beaumont

Cornish Limited

Canaccord Genuity Limited

Cenkos

Securities Plc

Peterhouse Capital

Limited

TB Cardew

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Richard Reed

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Rees

Alex Aylen (Head of Equities)

Giles Balleny

Michael Johnson

Lucy Williams

Charles Goodfellow

Ed Orlebar

Alistair Walker

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

+44 (0) 20 7930 0777

+44 (0) 7738 724 630

agronomics@tbcardew.com

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBLLFBXELXBBQ
Date   Source Headline
23rd Dec 201612:00 pmRNSFinal Results and Notice of AGM
22nd Dec 20162:41 pmRNSLoan to the Diabetic Boot Company Ltd
12th Oct 20167:00 amRNSNet Asset Value(s)
22nd Jul 20167:00 amRNSNet Asset Value(s)
29th Apr 20167:00 amRNSNet Asset Value calculation to 31 March 2016
15th Apr 20167:00 amRNSChange of Adviser
18th Mar 20167:00 amRNSHolding(s) in Company
17th Mar 20167:00 amRNSInterim Results for the six months to 31 Dec 2015
10th Feb 201612:11 pmRNSResult of AGM
25th Jan 20167:00 amRNSNet Asset Value(s)
22nd Dec 20157:00 amRNSAnnual Audited Results and Notice of AGM
17th Dec 20154:00 pmRNSDBC receives US FDA approval to market PulseFlowDF
4th Nov 20157:00 amRNSNet Asset Value(s)
30th Jul 20157:01 amRNSNet Asset Value(s)
15th Apr 20157:00 amRNSNet Asset Value as at 31 March 2015
30th Mar 20157:00 amRNSInterim results for 6 months to 31 December 2014
6th Feb 201512:21 pmRNSClose of Tender Offer
4th Feb 20155:36 pmRNSRe Results of Tender Offer
2nd Feb 20158:00 amRNSResults of Tender Offer
23rd Jan 20157:00 amRNSHolding(s) in Company
15th Jan 201511:56 amRNSHolding(s) in Company
14th Jan 20157:00 amRNSTender Offer
12th Jan 20159:32 amRNSNet Asset Value
30th Dec 20147:00 amRNSAnnual audited results
23rd Dec 201411:58 amRNSHolding(s) in Company
28th Nov 20142:04 pmRNSTender Offer in respect of Magna Biopharma
21st Oct 20147:00 amRNSNet Asset Value to 30 September 2014
22nd Jul 20147:00 amRNSNet Asset Value(s)
8th Apr 20147:00 amRNSNet Asset Value calculations to 31 March 2014
31st Mar 20147:00 amRNSInterim Results for the six months to 31 Dec 2013
24th Jan 201411:21 amRNSHolding(s) in Company
20th Jan 201410:56 amRNSHolding(s) in Company
17th Jan 20147:00 amRNSNet Asset Value(s)
15th Jan 20147:00 amRNSAppointment of Nominated Adviser
6th Jan 20145:49 pmRNSHolding(s) in Company
20th Nov 20134:04 pmRNSHolding(s) in Company
13th Nov 20135:13 pmRNSHolding(s) in Company
12th Nov 20137:00 amRNSResult of General Meeting
24th Oct 20137:01 amRNSNotice of General Meeting
24th Oct 20137:00 amRNSAnnual Financial Report
18th Oct 201311:23 amRNSHolding(s) in Company
18th Oct 20137:00 amRNSNet Asset Value(s)
4th Oct 20132:13 pmRNSHolding(s) in Company
26th Sep 20135:10 pmRNSHolding(s) in Company
13th Sep 201311:32 amRNSHolding(s) in Company
6th Sep 20135:29 pmRNSHolding(s) in Company
6th Aug 20139:40 amRNSHolding(s) in Company
11th Jul 20137:00 amRNSNet Asset Value(s)
15th Apr 201312:34 pmRNSDirectorate Change
12th Apr 20132:17 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.